

ESMO ADVANCED COURSE PROGRAMME

ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: BREAST, GYNAECOLOGICAL AND GI CANCERS

Singapore
11-12 October 2024

CHAIRS Elizabeth Smyth, United Kingdom
David S. P. Tan, Singapore

SPEAKERS Tom W.-W. Chen, Taiwan
Rebecca A. Dent, Singapore
Elisa Fontana, United Kingdom
Joline Lim, Singapore
Josh C. C. Lin, Taiwan
Brigette Ma, Hong Kong SAR, China
Caterina Marchiò, Italy

LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

Friday, 11 October 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and Learning Objectives Introduction
Elizabeth Smyth, UK and David S. P. Tan, SG

09:10-10:15 **Session 1 – ADC Development and pharmacodynamics – Part I**
Chair: Elizabeth Smyth, UK

20' ADC development: What are the considerations in early phase trials
Josh C. C. Lin, TW

20' Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance
Tom W.-W. Chen, TW

25' Q&A

10:15-10:45 *Coffee break*

10:45-15:15	Workshop sessions
	Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)
	15' Introduction based on <u>clinical cases presented by speakers</u>
	40' Discussion
	5' Break
Workshop 1 60'	ADC trials in breast cancer Joline Lim, SG
Workshop 2 60'	ADC trials in GI cancers Elizabeth Smyth, UK
Workshop 3 60'	ADC trials in gynaecological cancer David S. P. Tan, SG
12:45-13:45	<i>Lunch</i>
13:45-14:45	Workshops continuation
14:45-15:15	Feedback on the workshops from each group
15:15-15:45	<i>Coffee break</i>
15:45-16:15	Session 2 – ADC Development and pharmacodynamics – Part II
20'	Toxicity: Prediction, identification and treatment Rebecca A. Dent, SG
10'	Q&A
19:30	<i>Networking dinner</i>

Saturday, 12 October 2024

- 09:00-10:25 **Session 3 – Target assessment, rational combos and future gazing – Part I**
Chair: David S. P. Tan, SG
- 20' Considerations from pathology: Biomarker selection, on target off tumour expression off target toxicities
Caterina Marchiò, IT
- 35' Developments in ADC constructs including: Bispecific ADCs, cytokine, peptide based conjugates
Elisa Fontana, UK
- 30' Q&A
- 10:25-10:55 Coffee break*
- 10:55-11:35 **Session 4 – Target assessment, rational combos and future gazing – Part II**
Chair: Elizabeth Smyth, UK
- 20' How to develop rational combinations and sequencing
Brigette Ma, HK SAR, CN
- 20' Q&A
- 11:35-11:50 **Synthesis and wrap-up**
Elizabeth Smyth, UK and David S. P. Tan, SG
- 11:50-13:00 Lunch*